3.12. acute infective epididymitis. 3.12.1. epidemiology, aetiology pathophysiology epididymitis common condition incidence ranging 25 65 cases per 10,000 adult males per year acute, chronic recurrent . acute epididymitis clinically characterised pain, swelling increased temperature epididymis, may involve testis scrotal skin. generally caused migration pathogens urethra bladder identified appropriate diagnostics 90% patients . torsion spermatic cord (testicular torsion) important differential diagnosis boys young men. predominant pathogens isolated enterobacterales (typically e. coli), c. trachomatis n. gonorrhoeae . men anal intercourse abnormalities urinary tract resulting bacteriuria higher risk epididymitis caused enterobacterales . mumps virus considered viral prodromal symptoms salivary gland enlargement. tuberculous epididymitis may occur, typically chronic epididymitis, high-risk groups men immunodeficiency high prevalence countries, frequently results discharging scrotal sinus. brucella candida spp. rare possible pathogens. 3.12.2. diagnostic evaluation culture mid-stream specimen urine performed previous urine culture results checked. sexually transmitted infections including c. trachomatis n. gonorrhoeae detected naat first voided urine urethral swab. urethral swab smear performed gram staining culture n. gonorrhoeae, available . detection pathogens reported according local procedures. patients probable sexually transmitted infections (stis) advised attend appropriate clinic screened stis. men enterobacterales may require investigation lower urinary tract abnormalities. tuberculous epididymitis suspected, three sequential early morning urine samples cultured acid-fast bacilli (afb) sent screening naat m. tuberculosis dna . appropriate prostate secretion, ejaculate, discharge draining scrotal fistula, well fine needle aspiration biopsy specimens investigated using microscopy, afb culture naat. scrotal ultrasound accurate diagnose acute epididymitis urinalysis alone may also beneficial exclusion pathologies . 3.12.3. disease management men suspected sti informed risks others advised sex free infection. empirical antimicrobial therapy chosen consideration probable pathogen degree penetration inflamed epididymis may need varied according local pathogen sensitivities guidance. generally, c. trachomatis enterobacterales covered initially regimen modified according pathogen identification. doxycycline specific fluoroquinolones good clinical microbiological cure rates patients suspected c. trachomatis m. genitalium achieve adequate levels inflamed male genital tissues oral dosing. macrolide antibiotics azithromycin effective c. trachomatis tested epididymitis; however, initial pharmacokinetic studies suggest azithromycin may effectively penetrate epididymal tissue given multiple doses . fluoroquinolones remain effective oral treatment enterobacterales although resistance increasing local advice sought. fluoroquinolones considered gonorrhoea. single high parenteral dose third-generation cephalosporin effective n. gonorrhoeae; current resistance patterns local public health recommendations guide choice agent. clinical response antibiotics men severe epididymitis assessed approximately three days. men likely proven sti assessed fourteen days check cure ensure tracing treatment contacts according local public health recommendations. 3.12.4. evidence summary relating chapter, four guidelines based systematic reviews identified . evidence quality assessments detailed. high quality rct demonstrated ten-day course ciprofloxacin superior pivampicillin clinical cure (80% vs. 60%) men aged > 40 years . data large comparative case series suggested young age history sexual activity sufficiently predictive sexually transmitted pathogen guide antibiotic treatment acute epididymitis . empiric antibiotic regimens existing guidelines panel consensus: 1. men acute epididymitis low risk gonorrhoea (e.g. discharge) single agent combination two agents sufficient dose duration eradicate c. trachomatis enterobacterales used. appropriate options are: a. fluoroquinolone active c. trachomatis orally daily ten fourteen days*orb. doxycycline 200 mg initial dose mouth 100 mg twice daily ten fourteen days* plus antibiotic active enterobacterales** ten fourteen days* 2. men likely gonorrhoeal acute epididymitis combination regimen active gonococcus c. trachomatis must used as: a. ceftriaxone 1000 mg intramuscularly single dose plus doxycycline 200 mg initial dose mouth 100 mg twice daily ten fourteen days* 3. non-sexually active men acute epididymitis single agent sufficient dose duration eradicate enterobacterales used. appropriate option fluoroquinolone mouth daily ten fourteen days* *depending upon pathogen identification clinical response.** parenteral option required men severe infection requiring hospitalisation. surgical exploration may required drain abscesses debride tissue. comparative cohort study found lack separation epididymis testis palpation presence abscess us may predict requirement surgery following initial antibiotic treatment . cohort study found semen parameters may impaired epididymitis recovered following successful treatment . comparative clinician cohort studies suggest adherence guidelines assessment treatment epididymitis low, particularly urologists compared sexual health specialists primary care physicians . 3.12.5. screening large cohort screening study carriage c. trachomatis including randomly selected group 5,000 men 1,033 tested showed benefit terms reduction risk epididymitis nine years observation . 3.12.6. summary evidence recommendations diagnosis treatment acute infective epididymitis summary evidencelein young sexually active patients stis enterobacterales considered aetiological agents.3in patients > 40 years antibiotic therapy ciprofloxacin superior pivmecillinam.1ba negative sexual risk history exclude stis sexually active men.3 recommendationsstrength ratingobtain mid-stream urine first voided urine pathogen identification culture nucleic acid amplification test.stronginitially prescribe single antibiotic combination two antibiotics active chlamydia trachomatis enterobacterales young sexually active men; older men without sexual risk factors enterobacterales considered.strongif gonorrhoeal infection likely give single dose ceftriaxone 1000 mg intramuscularly intravenously* addition course antibiotic active chlamydia trachomatis.strongadjust antibiotic agent pathogen identified adjust duration according clinical response.weakfollow national policies reporting tracing/treatment contacts sexually transmitted infections.strong *despite lack rcts increasing evidence intravenous treatment ceftriaxone safe effective treatment gonorrhoeal infections avoids discomfort intramuscular injection patients figure 2: diagnostic treatment algorithm men acute epididymitisi.m. = intramuscular; i.v. intravenously.* despite lack rcts increasing evidence intravenous treatment ceftriaxone safe effective treatment gonorrhoeal infections avoids discomfort intramuscular injection patients .